Xeris Biopharma Holdings, Inc. (XERS): Shareholders' Equity
$13.69M
As of 2025-12-31
-$9.73M
As of 2026-06-30
-32.8%
3-year compound annual growth
-16.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.69M | n/m | 2026-03-02, Balance as of period end |
| 2024-12-31 | -$29.61M | n/m | 2026-03-02, Balance as of period end |
| 2023-12-31 | -$6.78M | n/m | 2026-03-02, Balance as of period end |
| 2022-12-31 | $45.19M | -52.6% | 2025-03-06, Balance as of period end |
| 2021-12-31 | $95.23M | +182.1% | 2024-03-06, Balance as of period end |
| 2020-12-31 | $33.76M | n/a | 2022-03-11, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $13.69M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | -$261.83M | n/m |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$23.11M | n/m |
| CorMedix Inc. (CRMD) | 2025-12-31 | $405.31M | +378.8% |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
Compare XERS, IRWD, EOLS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗